Similar articles

• Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group Trial.

  Gams RA, Nelson O, Birch R. Gams RA, et al. Cancer Treat Rep. 1986 Jul;70(7):921-2. Cancer Treat Rep. 1986. PMID: 3521848 Clinical Trial. No abstract available.
• Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study.

  Cowan JD, Von Hoff DD, McDonald B, Talley RW, McCracken JD, Chen T. Cowan JD, et al. Cancer Treat Rep. 1982 Sep;66(9):1779-80. Cancer Treat Rep. 1982. PMID: 7116355 No abstract available.
• Phase II evaluation of mitoxantrone in advanced carcinoma of the stomach: a Southeastern Cancer Study Group Trial.

  DeSimone PA, Gams R, Birch R. DeSimone PA, et al. Cancer Treat Rep. 1986 Aug;70(8):1043-4. Cancer Treat Rep. 1986. PMID: 3524836 Clinical Trial. No abstract available.
• Sorafenib for the treatment of advanced renal cell carcinoma.

  Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R. Kane RC, et al. Clin Cancer Res. 2006 Dec 15;12(24):7271-8. doi: 10.1158/1078-0432.CCR-06-1249. Clin Cancer Res. 2006. PMID: 17189398 Review.
• [The role of chemotherapy in metastatic pulmonary tumors in a disease-oriented phase II study of anticancer agent].

  Fujita J, Saijo N. Fujita J, et al. Gan No Rinsho. 1985 Aug;31(10):1241-6. Gan No Rinsho. 1985. PMID: 3903252 Review. Japanese.